세계 이산화탄소 제거 기기(체외형) 시장은 2024년부터 2030년까지 예측 기간 동안 10.32%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다. 이산화탄소 제거 기기(체외형)에 대한 수요는 주로 만성폐쇄성폐질환(COPD), 천식, 급성호흡곤란증후군(ARDS)과 같은 호흡기 질환 증가, 고령화 인구 증가와 좌식 생활습관, 제품 포트폴리오의 제품 개발 활동으로 인한 잠재적 위험요인으로 인해 증가하고 있습니다, 이에 따라 2024-2030년의 예측 기간 동안 이산화탄소 제거 기기(체외형) 시장의 전반적인 성장에 기여하고 있습니다.
또한, 호흡기 질환에 대한 의료비 지출과 연구비 증가는 이산화탄소 제거 기기(체외) 시장 수요를 촉진할 것으로 예상됩니다. 따라서 위의 모든 요인의 상호 작용은 예측 기간 동안 전체 이산화탄소 제거 기기(체외) 시장에 긍정적인 영향을 미칠 것으로 예상됩니다.
그러나 체외 이산화탄소 제거 요법 중 발생할 수 있는 환자 관련 합병증 및 기계적 합병증과 같은 위험은 예측 기간 동안 전체 이산화탄소 제거 기기(체외) 시장의 성장을 제한할 수 있습니다.
모든 지역 중 북미는 2023년 이산화탄소 제거 기기(체외형) 시장에서 가장 큰 점유율을 차지할 것으로 추정되며, COPD 및 ARDS와 같은 호흡기 질환의 유병률 증가, 노인 인구 증가, 정부 이니셔티브, 고도로 발달된 의료 인프라, 인구의 이산화탄소 제거 기기(체외형)의 조기 도입과 같은 주요 성장 요인의 중요성으로 인해 북미 시장은 향후 몇 년동안 활성화될 것으로 예상됩니다.
이 보고서는 세계 이산화탄소 제거 기기(체외형) 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별/용도별/최종사용자별/지역별 동향, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.
Carbon Dioxide Removal Devices (Extracorporeal) Market By Product Type (Extracorporeal Co2 Devices, Disposables, And Others), Application (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Acute Respiratory Distress Syndrome (ARDS), And Others), End-User (Hospitals, Clinics, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence of respiratory and stress related disorders and various product development activities in the carbon dioxide removal devices (extracorporeal) around the globe.
The global carbon dioxide removal devices (extracorporeal) market is estimated to grow at a CAGR of 10.32% during the forecast period from 2024 to 2030. The demand for carbon dioxide removal devices (extracorporeal) is primarily being boosted owing to an increase in the number of respiratory disorders such as chronic obstructive pulmonary disorder (COPD), asthma, Acute Respiratory Distress Syndrome (ARDS) among others, a growing aging population and sedentary lifestyles serving as potential risk factors, along with product development activities in the product portfolio, thereby contributing in the overall growth of the carbon dioxide removal devices (extracorporeal) market during the forecast period from 2024-2030.
Carbon Dioxide Removal Devices (Extracorporeal) Market Dynamics:
According to the World Health Organization (WHO) 2022, it was estimated that worldwide around 262 million people were suffering from asthma in 2019.
As per the Asthma and Allergy Foundation of America 2022, approximately 25 million people in the United States were suffering from asthma in the year 2020. The same source also stated that in 2020, about 20 million United States adults aged 18 and above were suffering from asthma.
The Asthma and Lung UK Organization 2022 also stated that in the UK, about 5.4 million people suffer from asthma disorder in 2021. The number accounts for about one in every 12 adults and one in every 11 children.
Moreover, as per statistics published by National Health Science (2022), about 1.17 million people in England were diagnosed with COPD in 2020-21, accounting for 1.9% of the total population. Also, according to a study published in PLOS ONE in 2021, about 2.6 million people were suffering from COPD in France. By 2025, that number is expected to rise to 2.8 million.
In addition, the growing healthcare expenditure and research spending for respiratory disorders are also expected to spur the market demand for extracorporeal CO2 removal devices. For example, in May 2022, as per NIH, Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC), about USD 150 million was spent on research for COPD in the United States 2022. Therefore, the interplay of all the above-mentioned factors is expected to have a positive impact on the overall market for carbon dioxide removal devices (extracorporeal) during the forecast period.
However, the risks of patient-associated complications and mechanical complications that may arise during extracorporeal CO2 removal therapy, among others may restrict the growth of the overall market for carbon dioxide removal devices (extracorporeal) during the forecast period.
Carbon Dioxide Removal Devices (Extracorporeal) Market Segment Analysis:
Carbon Dioxide Removal Devices (Extracorporeal) Market by Product Type (Extracorporeal CO2 Devices, Disposables, and Others), Application (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Acute Respiratory Distress Syndrome (ARDS), and Others), End-User (Hospitals, Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the application segment of the carbon dioxide removal devices (extracorporeal) market, the COPD category is expected to amass a significant revenue share in the year 2023. This can be attributed to the rising prevalence of COPD among various high-income countries and the technical advantages of extracorporeal CO2 devices for COPD are expected to spur its market demand during the given forecast period.
As per a recent European Respiratory Journal article, an estimated 36.5 million Europeans were suffering from COPD during the pandemic in November 2021, and this number is projected to reach 49.4 million by 2050.
Moreover, the ERS Journal in August 2022, stated that about 645.6 million people were estimated to have COPD by 2050, which marked a relative increase of 36% as compared to 2021.
In addition, the latest extracorporeal CO2 devices for COPD patients were comparatively less complex and compatible while working owing to the only requirement of a tiny double-lumen cannula and their low blood flow rates.
Therefore, due to the interplay of all the above-mentioned factors, the COPD category in the application segment is expected to rise, which is anticipated to bolster the demand for more extracorporeal CO2 devices, thereby driving the growth of the overall Carbon Dioxide Removal Devices (Extracorporeal) market during the forecast period from 2024-2030.
North America Is Expected To Dominate The Overall Carbon Dioxide Removal Devices (Extracorporeal) Market:
Among all the regions, North America is estimated to account for the largest share of the Carbon Dioxide Removal Devices (Extracorporeal) market in the year 2023. Owing to the significance of key growth factors such as the increasing prevalence of respiratory disorders like COPD and ARDS, the rising geriatric population, government initiatives, the presence of a highly developed healthcare infrastructure, early uptake of extracorporeal CO2 devices among the population among others, are expected to spur the market in North America in the upcoming years.
As per a recent NLM article in August 2022, acute respiratory distress syndrome (ARDS) affects 200,000 people in critical illness settings in the United States every year on average. The aforementioned source further stated that chronic lower respiratory disease (CLRD) is the fourth leading cause of death in the United States.
The growing healthcare expenditure and research spending on respiratory diseases in North America are also expected to spur the market demand for extracorporeal CO2 removal devices.
Additionally, government initiatives such as the CDC's National Asthma Control Program (NACP) which provides funds for educating asthma-affected patients, are strongly expected to enhance mass awareness regarding respiratory disorders.
Thus, owing to all the above-stated factors, the regional market in North America is expected to witness a significantly higher product demand, thus driving the overall regional market for North America Carbon Dioxide Removal Devices (Extracorporeal).
Carbon Dioxide Removal Devices (Extracorporeal) Market Key Players:
Some of the key market players operating in the Carbon Dioxide Removal Devices (Extracorporeal) market include Getinge AB, ESTOR S.P.A, Alung Technologies, Medica Spa, Medtronic, X-COR Therapeutics, Xenios AG, Aferectica Srl, and others.
Recent Developmental Activities In The Carbon Dioxide Removal Devices (Extracorporeal) Market:
Key Takeaways From The Carbon Dioxide Removal Devices (Extracorporeal) Market Report Study
Target Audience Who Can Benefit From This Carbon Dioxide Removal Device (Extracorporeal) Market Report Study
Frequently Asked Questions For The Carbon Dioxide Removal Devices (Extracorporeal) Market:
Carbon Dioxide Removal Devices (Extracorporeal) are specialized devices that primarily focus on CO2 removal, significantly reducing the PaCO2. The potential advantage of these devices is the reduced blood flow through the circuit, where oxygenation by the lungs and dependence on the alveoli reduces with independent extracorporeal oxygenation through apnoeic oxygenation.
The carbon dioxide removal devices (extracorporeal) market is estimated to grow at a CAGR of 10.32% during the forecast period from 2024 to 2030.
The demand for carbon dioxide removal devices (extracorporeal) is primarily being boosted owing to an increase in the number of respiratory disorders such as chronic obstructive pulmonary disorder (COPD), asthma, Acute Respiratory Distress Syndrome (ARDS) among others, a growing aging population and sedentary lifestyles serving as potential risk factors, along with product development activities in the product portfolio, thereby contributing in the overall growth of the carbon dioxide removal devices (extracorporeal) market during the forecast period from 2024-2030.
Some of the key market players operating in the Carbon Dioxide Removal Devices (Extracorporeal) market include Getinge AB, ESTOR S.P.A, Alung Technologies, Medica Spa, Medtronic, X-COR Therapeutics, Xenios AG, Aferectica Srl, and others.
North America is expected to dominate the overall carbon dioxide removal devices (extracorporeal) market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the increasing prevalence of respiratory disorders like COPD and ARDS, the rising geriatric population, government initiatives, the presence of a highly developed healthcare infrastructure, early uptake of extracorporeal CO2 devices among the population among others, are expected to spur the market in North America in the upcoming years.